Policy review demands better quality of life data in cancer clinical trials
A new policy review from Common Sense Oncology (CSO) and the European Organisation for Research and Treatment of Cancer (EORTC) calls for quality of life data to play a more central role in clinical trials evaluating adjuvant cancer treatments.
Read original article on The Medical News →Related news
-
New fluorescent paper strips make vitamin B12 testing simpler
United Kingdom
-
Robotic assisted hip and knee replacements shows no clear benefit over conventional methods
United Kingdom
-
Before the first bite: A missing gut protein may set the stage for peanut allergy
United Kingdom
-
Discovery explains how immune cells target DNA mutations to improve antibodies
United Kingdom
-
Gut bacterial metabolite worsens brain damage after stroke, study finds
United Kingdom
-
New framework maps depression symptoms to unique brain circuits
United Kingdom
-
Sleep hours miss part of story: Young adults lose sleep quality, not hours, amid heat, noise and light
United Kingdom
-
New recommendations for serrated polyposis syndrome
United Kingdom